Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 10:2021:5592693.
doi: 10.1155/2021/5592693. eCollection 2021.

Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers

Shi-Han Yang  1 , Can-Tong Liu  2   3 , Chao-Qun Hong  4 , Ze-Yuan Huang  1 , Huan-Zhu Wang  1 , Lai-Feng Wei  2   3 , Yi-Wei Lin  2   3 , Hai-Peng Guo  5 , Yu-Hui Peng  2   3   6 , Yi-Wei Xu  2   3   6
Affiliations
Free PMC article

Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers

Shi-Han Yang et al. Dis Markers. .
Free PMC article

Abstract

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are two predominant histological types of nonmelanoma skin cancer (NMSC), lacking effective early diagnostic markers. In this study, we assessed the diagnostic value of autoantibodies against p53, MMP-7, and Hsp70 in skin SCC and BCC. ELISA was performed to detect levels of autoantibodies in sera from 101 NMSC patients and 102 normal controls, who were recruited from the Cancer Hospital of Shantou University Medical College. A receiver operator characteristic curve was used to evaluate the diagnostic value. The serum levels of autoantibodies against p53, MMP-7, and Hsp70 were higher in NMSCs than those in the normal controls (all P < 0.01). The AUC of the three-autoantibody panel was 0.841 (95% CI: 0.788-0.894) with the sensitivity and specificity of 60.40% and 91.20% when differentiating NMSCs from normal controls. Furthermore, measurement of this panel could differentiate early-stage skin cancer patients from normal controls (AUC: 0.851; 95% CI: 0.793-0.908). Data from Oncomine showed that the level of p53 mRNA was elevated in BCC (P < 0.05), and the Hsp70 mRNA was upregulated in SCC (P < 0.001). This serum three-autoantibody panel might function in assisting the early diagnosis of NMSC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Study profile. ELISA: enzyme-linked immunosorbent assay.
Figure 2
Figure 2
Serum autoantibody measurements in study subjects. (a) The OD values of autoantibodies against p53, MMP-7, and Hsp70 were detected from patients with NMSCs and normal controls. (b) The levels of autoantibodies against p53, MMP-7, and Hsp70 were shown in squamous cell carcinoma and basal cell carcinoma. ns: no statistical significance.
Figure 3
Figure 3
Diagnostic performance of the individual autoantibodies and the autoantibody panel in the detection of skin cancer. (a) Receiver operating characteristic (ROC) curves for the ability to distinguish individuals with skin cancer from normal controls. (b) ROC curves for the ability to distinguish individuals with early-stage skin cancer from normal controls. (c) ROC curves for the ability to distinguish patients with squamous cell carcinoma from normal controls. (d) ROC curves for the ability to distinguish patients with basal cell carcinoma from normal controls.
Figure 4
Figure 4
Levels of individual autoantibodies in patients with skin cancer after surgical resection.
Figure 5
Figure 5
Rate of positive results for p53, MMP-7, Hsp70, and the panel in patients with NMSC according to the clinicopathological variables of tumors.
Figure 6
Figure 6
RNA-sequencing data of gene expression of p53, MMP-7, and Hsp70 from Oncomine in SCC, BCC, and corresponding normal tissues. (a) Hierarchical clustering of mRNA expression level of p53, MMP-7, and Hsp70 between patients with skin cancer and controls. (b) The combination of scatter plots and box plots to exhibit the mRNA expression level of p53, MMP-7, and Hsp70 between patients with skin cancer and controls. P values were analyzed by Students' t-test. ∗P < 0.05; ∗∗P < 0.001. ns: no statistical significance; NC: normal control; BCC: basal cell carcinoma; SCC: squamous cell carcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bowden G. T. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nature Reviews. Cancer. 2004;4(1):23–35. doi: 10.1038/nrc1253. - DOI - PubMed
    1. Youssef K. K., Van Keymeulen A., Lapouge G., et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nature Cell Biology. 2010;12(3):299–305. doi: 10.1038/ncb2031. - DOI - PubMed
    1. Cameron M. C., Lee E., Hibler B. P., et al. Basal cell carcinoma: contemporary approaches to diagnosis, treatment, and prevention. Journal of the American Academy of Dermatology. 2019;80(2):321–339. doi: 10.1016/j.jaad.2018.02.083. - DOI - PubMed
    1. Marcil I., Stern R. S. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Archives of Dermatology. 2000;136(12):1524–1530. doi: 10.1001/archderm.136.12.1524. - DOI - PubMed
    1. Que S. K. T., Zwald F. O., Schmults C. D. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. Journal of the American Academy of Dermatology. 2018;78(2):237–247. doi: 10.1016/j.jaad.2017.08.059. - DOI - PubMed